MoCRA for Amazon sellers starts with two separate questions: who manufactures or processes the cosmetics, and whose name appears on the label? Facility owners or operators handle registration where required; the responsible person identified on the label handles product listing and other responsible-person duties. Selling through Amazon or using FBA does not identify those parties for you.
Start with the role table, then assess exemptions. This guide explains FDA’s framework; it does not classify a particular product as a cosmetic or drug or determine a particular company’s legal obligations.
| Your business model | Registration question | Listing and responsible-person question |
|---|---|---|
| Private label brand using a contract factory | Does the factory need to register its manufacturing or processing facility? | Is your company the manufacturer, packer, or distributor named on the label? |
| Brand manufacturing its own cosmetics | Does your facility fall within registration requirements or an exemption? | Is your company the responsible person for the products? |
| Reseller of another brand’s sealed products | Do you operate any relevant manufacturing or processing facility? | Whose qualifying name appears on the label, rather than merely on the Amazon offer? |
| Business considering the small business exemption | Does the relevant entity meet the sales definition and product conditions? | Does the exemption apply to the responsible person and product concerned? |
The table applies FDA’s role definitions; it is not a determination about a specific seller. FDA sources checked November 7, 2026: the MoCRA overview, registration and listing page, and registration and listing guidance.
MoCRA for Amazon Sellers: Registration and Listing Are Different
FDA defines the responsible person as the manufacturer, packer, or distributor whose name appears on the cosmetic product’s label under the relevant labeling provisions. The name of a storefront, an invoice recipient, or an advertising account is not a substitute for reviewing the label. FDA’s registration and listing page was checked November 7, 2026.
Facility registration follows manufacturing or processing
FDA’s registration guidance describes registration by the person who owns or operates a facility manufacturing or processing cosmetics for US distribution, subject to applicable exemptions. A private label brand should identify the actual manufacturing or processing establishment and the party managing its registration, rather than assuming its own product listing covers the factory.
FDA’s current registration page says facilities renew registration every two years from the initial registration date, checked November 7, 2026. Build a calendar from the facility’s actual renewal date. A general annual supplier review is useful, but it is not the same as tracking that biennial renewal.
Product listing follows the responsible person
FDA says the responsible person must list each marketed cosmetic product, including ingredients, and provide updates annually, checked November 7, 2026. Keep the product identity, formula records, and label version connected so the submission can be reviewed against the actual product.
FDA provides Cosmetics Direct for registration and listing submissions. Its public registration page also describes alternative electronic and paper submission routes. This guide has not tested a submission or a logged-in account.
For a contract-manufactured brand, write down who maintains the facility record, who handles the product listing, and who receives formulation changes. Hiring someone to prepare a submission does not resolve the underlying question of which entity carries the duty.
Check the Small Business Exemption Without Broad Shortcuts
The small business exemption is narrower than a general exemption from MoCRA. Assess the sales definition and the product exclusions separately, then document which entity and products your assessment covers.
The sales definition includes inflation adjustment
FDA’s final registration and listing guidance, checked November 7, 2026, describes small businesses as responsible persons and facility owners or operators whose average gross annual US cosmetic-product sales over the previous three-year period are less than $1,000,000, adjusted for inflation, and who do not engage in manufacturing or processing the specified excluded products.
That is not the same as all company revenue, one year’s Amazon sales, or an unadjusted permanent dollar cutoff. The FDA guidance recommends the Bureau of Economic Analysis’s annually updated Implicit Price Deflator for GDP when adjusting for inflation. This guide does not present a calculated inflation-adjusted threshold for the current year.
Keep the sales records, averaging period, inflation-adjustment basis, and entity identification together. A spreadsheet with only a headline annual sales figure does not explain how the exemption assessment was reached.
The four product exclusions need their full conditions
FDA’s registration page, checked November 7, 2026, states that the exemption does not apply to facilities that manufacture or process, or responsible persons for, these products:
- Products that regularly contact the mucus membrane of the eye under customary or usual conditions of use.
- Products that are injected.
- Products intended for internal use.
- Products intended to alter appearance for more than 24 hours under customary or usual conditions of use, where consumer removal is not part of those conditions of use.
Avoid replacing the first condition with all eye-area products. Likewise, a marketing claim about long wear does not eliminate the need to consider the full fourth condition, including consumer removal. Evaluate intended use and the complete wording rather than deciding from a broad category nickname.
Exemption is not the end of the file
FDA’s MoCRA overview identifies small business exemptions from GMP, registration, and product listing requirements, checked November 7, 2026. It does not describe those exemptions as removing safety substantiation and serious adverse event reporting duties.
Keep those remaining workstreams active even when a registration or listing exemption applies. If the product mix or relevant sales change, revisit the assessment instead of reusing an old exemption memo indefinitely.
Keep Safety and Adverse Event Responsibilities Separate
A submission record is not a safety file, and a safety file is not an adverse event response process. Assign ownership for each.
Maintain adequate safety substantiation records
FDA’s MoCRA overview says the responsible person must ensure and maintain records supporting adequate safety substantiation of its cosmetics, checked November 7, 2026. The same page says neither the law nor FDA regulations require specific tests to demonstrate the safety of individual products or ingredients.
Build a product-specific record connecting the formula, ingredients, intended use, relevant safety data, and supporting assessments. FDA says relevant existing safety data can be used, while emphasizing scientifically robust methods. A generic supplier statement with no clear connection to the marketed formula is difficult to review or update.
When a supplier changes the formula, packaging, or intended-use information, route the change to whoever maintains the safety records and listing information. The practical goal is a traceable file for the product actually being sold, not a folder of disconnected certificates.
Route serious adverse events promptly
FDA states that responsible persons must report serious adverse events associated with US use of their cosmetics within 15 business days after the responsible person receives the report, checked November 7, 2026 against FDA’s reporting explanation and the MoCRA statutory text linked by FDA, section 605(b). The report must include a copy of the label on or within the retail packaging.
FDA also states that medical or other information received about the event within one year of the initial report must be submitted within 15 business days after the responsible person receives that new information. Keep the initial report and follow-up information linked rather than treating the first submission as the end of the process.
Design a handoff for buyer messages, return explanations, and other complaints so potentially serious events reach the responsible person’s designated contact. Preserve the original wording, receipt information, product identifiers, available lot information, and label version. The customer-service team needs an escalation route; it should not have to reconstruct the responsible person’s identity during an incident.
FDA’s definition of serious adverse events includes outcomes such as hospitalization, infection, and significant disfigurement. Use the full definition in the linked MoCRA overview when designing the review process, rather than treating all complaints as equivalent.
What the October 2026 Recall Guidance Adds
FDA’s MoCRA overview announces that it issued final mandatory cosmetics recall guidance on October 29, 2026, checked November 7, 2026. The linked Questions and Answers Regarding Mandatory Cosmetics Recalls guidance identifies itself as final October 2026 guidance addressing implementation of section 611 of the FD&C Act.
This is recall-implementation guidance, not a new product registration certificate or evidence that every cosmetic needs an identical recall response. Its publication also does not establish that your particular product has been recalled.
FDA’s MoCRA overview describes the authority with conditions: FDA must determine a reasonable probability that a cosmetic is adulterated or misbranded and that use or exposure will cause serious adverse health consequences or death. FDA can order a mandatory recall if the responsible person refuses a voluntary recall. Those conditions matter; describing the authority only as a power to recall any noncompliant product loses important context.
For operational preparation, connect product and lot records to the responsible person’s recall contact. Keep an incident route that can bring together the supplier, product records, and inventory information. Use the Amazon product recalls guide for the separate marketplace operations topic.
Build a Usable Compliance File, Not an FDA Certificate Collection
FDA’s registration page explicitly says it does not issue certificates or other documents verifying compliance for cosmetic facility registration or product listing, checked November 7, 2026. That includes certificates, verification letters or emails, and documents confirming that registration or listing is not required.
FDA also says registration and listing are not an approval program. Assignment of a facility registration or product listing number does not indicate FDA approval of the facility or its cosmetics.
Organize the underlying records instead:
| Record group | What to keep connected |
|---|---|
| Identity and roles | Current label, responsible-person entity, manufacturer or processor, relevant contacts |
| Registration and listing | Applicable submission records and identifiers, facility renewal date, listing review calendar |
| Exemption assessment | Entity, sales calculation, inflation basis, product conditions, review date |
| Safety substantiation | Formula version, supporting data, assessment records, change history |
| Incident handling | Complaint intake, escalation owner, reports and follow-up information, recall contacts |
If Amazon requests documentation, archive the actual ASIN-specific request and map each item to the appropriate record. Do not substitute a supposed FDA approval certificate for evidence of the underlying activity.
For adjacent marketplace tasks, see Manage Your Compliance, category approval, and dangerous goods review. Those are separate questions from the FDA role assessment here.
Common Mistakes and Launch Checklist
The recurring errors are treating a factory’s registration as the brand’s product listing, equating small size with exemption from every duty, simplifying the excluded product conditions, and describing registration as approval.
Before launch or a supplier change:
- Review the actual label and identify the responsible person.
- Identify the manufacturing or processing facility and registration owner where applicable.
- Document any exemption assessment with its full sales and product basis.
- Connect the product listing record to the marketed formula and label.
- Confirm who maintains safety substantiation and receives product changes.
- Give complaint handlers an adverse event escalation contact and reporting workflow.
- Maintain facility renewal and annual listing review reminders.
- Preserve the actual marketplace documentation request separately from the FDA assessment.
Recheck the file when the underlying facts change. A label-name change, new formula, different facility, or new product type can affect more than one workstream.
Frequently Asked Questions
Does reselling another brand automatically make me the responsible person?
No. FDA’s definition turns on the qualifying manufacturer, packer, or distributor name on the label, not simply the act of offering the product on Amazon. Review your actual role and label before assigning responsible-person duties.
Does FDA issue a MoCRA exemption certificate?
FDA’s registration page says it does not issue documents confirming that a facility or responsible person need not register or list. Maintain the supporting exemption assessment instead of expecting an FDA-issued certificate.
Does FBA replace the brand’s safety records?
FBA is not identified as a replacement for the responsible person’s safety substantiation duty in FDA’s MoCRA framework. Keep the role assessment and safety file connected to the product regardless of the fulfillment arrangement.
